UpdatesPress Release

Anlon Healthcare reported strong Q1FY27 results with 163% revenue growth to ₹87.62 Cr and 133% PAT growth to ₹8.28 Cr.

Anlon Healthcare LimitedAHCL · Filed with the exchange

The company expanded into Finished Dosage Formulations via subsidiary acquisition.

Read the original filing(PDF)

No comments yet. Be the first.

More from Anlon Healthcare Limited

All announcements